Keyphrases
Early Prostate Cancer
100%
Radiotherapy
61%
Fractionation Schedules
51%
Overall Survival
41%
Prostate Cancer
41%
Stereotactic Body Radiotherapy
38%
Finland
38%
Quality of Life
30%
Patient Well-being
30%
Radiotherapy Treatment
30%
Treatment Schedule
30%
Male Population
30%
External Beam Radiotherapy
30%
Prostate Swelling
30%
Radiation Effects
30%
Age-standardized
30%
Comorbidity
30%
Health-related Quality of Life
30%
Radiation Therapy
30%
Acute Effects
30%
Performance Status
30%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
30%
Radium-223
30%
Prostate
30%
Palliative Radiotherapy
30%
End of Treatment
24%
Hazard Ratio
23%
Conventional Fractionation
23%
Prostate Cancer Survival
23%
Gleason Score
23%
Clinical Oncology
23%
Charlson Comorbidity Index
23%
Sexual Well-being
20%
Gastrointestinal
20%
Acute Toxicity
20%
Hypofractionation
15%
5-year Survival
15%
Metastasis-free Survival
15%
Prognostic Factors
15%
Biochemical Recurrence-free Survival
15%
Gastrointestinal Toxicity
15%
Prostate Cancer Risk
12%
National Comprehensive Cancer Network
12%
Life Data
12%
Cancer Risk Factors
12%
Planning Target Volume Margin
11%
Pain Relief
11%
Randomized Trial
10%
University Hospital
10%
Treatment Group
9%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
67%
Overall Survival
61%
Acute Side Effect
30%
Castration Resistant Prostate Cancer
30%
Acute Toxicity
30%
Radium Chloride Ra 223
30%
Comorbidity
30%
Prostate Specific Antigen
29%
Alkaline Phosphatase
24%
Bone Metastasis
18%
Gleason Score
15%
Cancer Specific Survival
15%
Metastasis Free Survival
10%
Biochemical Recurrence Free Survival
10%
Erectile Dysfunction
7%
Malignant Neoplasm
7%
Treatment Group
7%
Adverse Event
6%
Neutropenia
6%
Androgen Receptor
6%
Thrombocytopenia
6%
Anemia
6%
Progression Free Survival
6%
Leukopenia
6%
Retrospective Study
5%
Biochemical Recurrence
5%
Recurrence Risk
5%
Metastasis
5%
Life Expectancy
5%
Disease Exacerbation
5%
Medicine and Dentistry
Prostate Cancer
61%
Radiation Therapy
38%
Stereotactic Body Radiation Therapy
35%
External Beam Radiotherapy
30%
Magnetic Resonance Imaging
30%
Overall Survival
30%
Comorbidity
30%
Quality of Life
17%
Hazard Ratio
15%
Cancer Specific Survival
15%
Clinical Oncology
15%
Charlson Comorbidity Index
15%
Contouring
15%
Gleason Score
15%
Metastasis Free Survival
10%
Prognostic Factor
10%
Biochemical Recurrence Free Survival
10%
Gastrointestinal Toxicity
8%
Treatment Planning
7%
Clinical Trial
7%
Recurrence Risk
5%
Disease Exacerbation
5%
Retrospective Study
5%
Prostate Specific Antigen Test
5%
Biochemical Recurrence
5%
Metastatic Carcinoma
5%
Proportional Hazards Model
5%
Life Expectancy
5%
